AU2001266863A1 - Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids - Google Patents

Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Info

Publication number
AU2001266863A1
AU2001266863A1 AU2001266863A AU6686301A AU2001266863A1 AU 2001266863 A1 AU2001266863 A1 AU 2001266863A1 AU 2001266863 A AU2001266863 A AU 2001266863A AU 6686301 A AU6686301 A AU 6686301A AU 2001266863 A1 AU2001266863 A1 AU 2001266863A1
Authority
AU
Australia
Prior art keywords
hiv
aids
treatment
methods
antiretroviral therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266863A
Other languages
English (en)
Inventor
Jeannette Whitcomb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of AU2001266863A1 publication Critical patent/AU2001266863A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001266863A 2000-06-12 2001-06-12 Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids Abandoned AU2001266863A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59189400A 2000-06-12 2000-06-12
US09591894 2000-06-12
PCT/US2001/018882 WO2001096611A1 (en) 2000-06-12 2001-06-12 Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Publications (1)

Publication Number Publication Date
AU2001266863A1 true AU2001266863A1 (en) 2001-12-24

Family

ID=24368395

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266863A Abandoned AU2001266863A1 (en) 2000-06-12 2001-06-12 Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Country Status (8)

Country Link
EP (1) EP1292712A4 (zh)
JP (1) JP2004503253A (zh)
CN (1) CN1446265A (zh)
AU (1) AU2001266863A1 (zh)
BR (1) BR0111575A (zh)
CA (1) CA2411401A1 (zh)
WO (1) WO2001096611A1 (zh)
ZA (1) ZA200210003B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037644B1 (en) 1998-05-26 2006-05-02 Virologic, Inc. Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
CN105648037B (zh) * 2015-12-30 2020-06-05 南方医科大学 一种重组慢病毒在hiv表型耐药检测中的应用
CN105647947A (zh) * 2015-12-30 2016-06-08 南方医科大学 一种转移质粒及其构建方法和重组慢病毒
EP3510172B1 (en) * 2016-09-07 2023-11-29 St Vincent's Hospital Sydney Limited Methods of detecting hiv
WO2019009793A1 (en) * 2017-07-04 2019-01-10 Cavidi Ab METHOD FOR ASSESSING THE SENSITIVITY OF A VIRUS TO TREATMENT BY MEASURING ENZYMA ACTIVITY AND SYSTEM THEREOF

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917033A (en) * 1995-10-31 1999-06-29 University Of Medicine & Dentistry Of New Jersey Structure based design of inhibitors of HIV-1 reverse transcriptase
CN1209875A (zh) * 1996-01-26 1999-03-03 维科公司 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法
JPH11502727A (ja) * 1996-01-26 1999-03-09 イノジェネティックス・ナムローゼ・フェンノートシャップ 逆転写酵素遺伝子における薬剤により誘発された変異の検出方法
BR9911600A (pt) * 1998-05-26 2001-02-13 Virologic Inc Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo

Also Published As

Publication number Publication date
EP1292712A4 (en) 2005-04-20
CA2411401A1 (en) 2001-12-20
WO2001096611A1 (en) 2001-12-20
EP1292712A1 (en) 2003-03-19
CN1446265A (zh) 2003-10-01
JP2004503253A (ja) 2004-02-05
ZA200210003B (en) 2004-12-22
BR0111575A (pt) 2003-06-24

Similar Documents

Publication Publication Date Title
GB0111872D0 (en) Therapeutic agents and methods
AU2002234021A1 (en) Method and device for the treatment of vulnerable tissue site
AU2001294598A1 (en) Tissue treatment method and apparatus
AU2002341876A1 (en) Methods and devices for treating diseased blood vessels
IL157577A0 (en) Disposable underpants and method of providing the same
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
ZA200201161B (en) Methods of treating nuclear factor-kappa B mediated diseases and disorders.
EP1360965A4 (en) METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH A DECREASE OF THE EXPOSURE OF THE AOP-1 GENE OR AOP-1 AND MEANS FOR THE TREATMENT OF THE DISEASES
AU2003278816A8 (en) Ss-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
AU2001257069A1 (en) Photostimulaton treatment apparatus and methods for use
AU5758200A (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
EP1015642A4 (en) MEANS AND METHODS FOR RECORDING ANTIRETROVIRAL THERAPY WITH NUCLEOSIDE-REVERSE TRANSCRIPTASE INHIBITORS AND GUIDANCE TO THERAPEUTIC DECISIONS IN HIV / AIDS TREATMENT
AU2002255898A1 (en) Methods and apparatus for treating diseased tissue
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
EP1322779A4 (en) MEANS AND METHODS TO TRACE AN ANTIRETROVIRAL PROTEASE INHIBITOR THERAPY, AND THERAPEUTIC GUIDELINES FOR THE TREATMENT OF HIV / AIDS
AU2001222215A1 (en) Lumbago treating girdle
AU7516601A (en) Methods of treating viral diseases with il-18 and il-18 combinations
AU2001266863A1 (en) Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2002225241A1 (en) A device and method for treating the skin of a subject
PL354111A1 (en) Combined therapy for treating the both depression and anxiety